Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 150 participants.

Also called NCT07695701

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07695701
  • EU CT 2026-526068-19-00
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07695701. Allocation not applicable; no masking; primary purpose treatment. Start 2026-07 (anticipated); primary completion 2030-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis
Acronym
ASCEND-ATTR
Condition
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Condition
Amyloidosis
Condition
Amyloid Cardiomyopathy
Condition
Transthyretin Amyloidosis
Intervention (Drug)
Acoramidis (AG10) oral tablet
Lead sponsor
Eidos Therapeutics, a BridgeBio company (class: industry)

Record details

Record id
cardio:ct-nct07695701
Content hash
e43f4a5a9ecf422f3e124940319a42190e2025626fb17261eebe110baa04ac0c